Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18404228 | ASSAY FOR RAPID DETECTION OF CEREBROSPINAL FLUID LEAKS | January 2024 | August 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18447974 | BIOSENSOR SYSTEM WITH INTEGRATED MICRONEEDLE | August 2023 | April 2025 | Allow | 20 | 1 | 1 | No | No |
| 18319157 | METHODS AND RELATED ASPECTS FOR DETECTING UNLABELED BIOMOLECULES | May 2023 | January 2026 | Allow | 33 | 0 | 0 | Yes | No |
| 18176144 | DEVICES AND METHODS OF URINALYSIS FOR REAL-TIME MONITORING OF ORGAN HEALTH | February 2023 | September 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18099226 | DETECTION OF SARS-COV-2 PROTEINS AND MITOCHONDRIAL PROTEINS IN PLASMA NEURON-DERIVED EXTRACELLULAR VESICLES AND ASTROCYTE-DERIVED EXTRACELLULAR VESICLES | January 2023 | July 2025 | Abandon | 30 | 2 | 1 | No | No |
| 18088996 | Method and System for Exposing Hidden or Masked Antigenic Sites of Viral Specimens Present in Biosamples Using a Home-Based COVID-19 Rapid Lateral Flow Immunoassay Test | December 2022 | July 2025 | Allow | 30 | 2 | 2 | Yes | No |
| 17987181 | IMMUNOCHROMATOGRAPHIC DETECTION DEVICE | November 2022 | March 2024 | Allow | 16 | 1 | 0 | No | No |
| 18046911 | Mask-Based Diagnostic System using Exhaled Breath Condensate | October 2022 | June 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 17949157 | MEMBRANE BASED CHEMILUMINESCENCE IMMUNOCHROMATOGRAPHY ASSAY AND ITS USE | September 2022 | March 2026 | Abandon | 42 | 4 | 0 | Yes | No |
| 17882671 | COMPOSITIONS, KITS, AND METHODS FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE | August 2022 | November 2025 | Allow | 39 | 5 | 0 | Yes | No |
| 17813204 | DEVICES AND METHODS FOR MINIMIZING HOOK EFFECT INTEFERENCE IN IMMUNOASSAYS | July 2022 | June 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17835238 | ASSAY FOR RAPID DETECTION OF CEREBROSPINAL FLUID LEAKS | June 2022 | October 2023 | Allow | 17 | 0 | 0 | Yes | No |
| 17780508 | PROSTATE CANCER BIOMARKERS | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17774395 | METHOD FOR DIAGNOSING HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1)-RELATED DISEASE | May 2022 | February 2026 | Allow | 46 | 2 | 1 | Yes | No |
| 17713181 | SEQUENTIAL LATERAL FLOW DEVICE | April 2022 | February 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17628022 | ANTIBODY SPECIFICALLY BINDING TO WRS PROTEIN, AND USE THEREOF | January 2022 | February 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17577066 | OVERACTIVE BLADDER DIAGNOSTIC APPARATUS AND METHODS | January 2022 | October 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17560074 | ANTIGEN DETECTION METHOD AND KIT WITH FALSE POSITIVE SIGNAL REMOVED | December 2021 | November 2024 | Allow | 35 | 3 | 0 | No | No |
| 17511975 | DETECTION DEVICE USING LATERAL FLOW STRIP FOR DETECTION AND DETECTION METHOD THEREOF | October 2021 | April 2024 | Allow | 30 | 0 | 1 | Yes | No |
| 17598837 | USE OF A PS396 ASSAY TO DIAGNOSE TAUOPHATIES | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17481806 | REGENERABLE AFFINITY SENSORS AND ASSOCIATED METHODS | September 2021 | September 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17441386 | BIOMARKER CEREBLON FOR DIAGNOSING HEPATOCELLULAR CARCINOMA, AND NOVEL MONOCLONAL ANTIBODY SPECIFIC THERETO | September 2021 | July 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17459158 | METHOD FOR DETECTING TARGET SUBSTANCE, REAGENT FOR DETECTING TARGET SUBSTANCE | August 2021 | October 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17432700 | METHODS OF DETECTING SEPTIC ARTHRITIS, TRANSIENT SYNOVITIS AND OSTEOMYELITIS | August 2021 | May 2025 | Allow | 45 | 1 | 1 | No | No |
| 17395330 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION | August 2021 | November 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17310289 | SENSOR CHIP AND METHODS THEREOF | July 2021 | September 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17425197 | METHOD AND KIT FOR DISCRIMINATING BETWEEN PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | July 2021 | July 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17310054 | BIOMARKERS | July 2021 | October 2025 | Abandon | 51 | 2 | 1 | Yes | No |
| 17368116 | COMPOSITIONS AND METHODS FOR CHARACTERIZING ARTHRITIC CONDITIONS | July 2021 | December 2025 | Abandon | 53 | 2 | 0 | Yes | No |
| 17326472 | COMPETITIVE LATERAL FLOW ASSAY | May 2021 | August 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17292224 | Diagnosing Sepsis or Bacteremia by Detecting Peptidoglycan Associated Lipoprotein (PAL) in Urine | May 2021 | April 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17244636 | VELVET DISEASE TEST AND METHOD | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17214996 | SPECIMEN PREPARATION DEVICE | March 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17277880 | IMMUNOCHROMATOGRAPHIC TEST STRIP | March 2021 | January 2026 | Allow | 57 | 4 | 1 | Yes | No |
| 17277098 | Composition and Methods for Measuring Antibody Dynamics | March 2021 | June 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17195600 | Analytical Toilet for Assessing Analytes in Excreta | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17189711 | Mask-Based Diagnostic System using Exhaled Breath Condensate | March 2021 | August 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17269152 | SORBENT COMPOSITION FOR PRE-ANALYTICAL TREATMENT OF SAMPLES | February 2021 | August 2025 | Allow | 54 | 1 | 0 | Yes | No |
| 17268637 | METHOD FOR PURIFYING ANTIBODY OR ANTIBODY-LIKE MOLECULE | February 2021 | November 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17268480 | APPLICATIONS OF SERUM S100A8/A9 COMPLEX LEVEL IN PROGNOSIS ASSESSMENT OF ACUTE MYOCARDIAL INFARCTION | February 2021 | November 2025 | Abandon | 57 | 3 | 1 | Yes | No |
| 17268006 | Use of Reagent for Detecting Expression Level of Transferrin in Preparation of Diagnostic Reagent or Kit for Disease Caused by Imbalance of Intestinal Immune Tolerance | February 2021 | August 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17174268 | MONOCLONAL ANTIBODIES BINDING MCM5 | February 2021 | March 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17250609 | METHODS AND COMPOSITIONS FOR REMOVING BIOTIN INTERFERENCE FROM ASSAYS USING MOLECULAR TRAPS | February 2021 | November 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17159589 | LATERAL FLOW IMMUNOASSAY DEVICE WITH SEPARATION MEMBRANE | January 2021 | September 2025 | Allow | 55 | 5 | 0 | No | No |
| 17150997 | ELECTROPHORETIC SYSTEM AND METHOD FOR ANALYTE CAPTURE | January 2021 | May 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17248236 | SPECIES-SPECIFIC ANTIGEN SEQUENCES FOR TICK-BORNE RELAPSING FEVER (TBRF) AND METHODS OF USE | January 2021 | March 2026 | Allow | 60 | 5 | 1 | Yes | No |
| 17142739 | AIRBORNE CORONAVIRUS DETECTOR AND ALERTING SYSTEM | January 2021 | November 2024 | Abandon | 46 | 2 | 1 | Yes | No |
| 17117131 | TEST STRIP, AND MICROBIAL SENSOR DEVICE AND SENSING METHOD | December 2020 | October 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17111616 | MODIFIED PARTICLE, METHOD FOR MANUFACTURING MODIFIED PARTICLE, AND DETECTION APPARATUS | December 2020 | July 2025 | Abandon | 56 | 3 | 1 | Yes | No |
| 17104059 | Biosensor System with Integrated Microneedle | November 2020 | June 2024 | Allow | 43 | 2 | 1 | No | No |
| 17087372 | CONCENTRATION ASSAY | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | Yes | No |
| 17082223 | SYSTEMS AND METHODS FOR SAMPLE PREPARATION | October 2020 | November 2025 | Abandon | 60 | 3 | 2 | No | No |
| 17065488 | Mask-Based Testing System for Detecting Biomarkers in Exhaled Breath Condensate, Aerosols and Gases | October 2020 | June 2025 | Allow | 56 | 1 | 1 | Yes | No |
| 17043961 | IN VITRO SCREENING METHOD AND KIT FOR EARLY DIAGNOSIS OF ORAL CAVITY TUMOURS | September 2020 | June 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17021671 | REAGENT KIT AND MEASUREMENT KIT FOR SERUM AMYLOID A | September 2020 | May 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 16997369 | MICROCHIP IMMUNOASSAY DEVICE HAVING PRECISE INCUBATION TIME CONTROL AND SIGNAL SCALING AND RELATED METHODS | August 2020 | March 2024 | Abandon | 43 | 3 | 0 | Yes | No |
| 16964870 | ASSAYING CELLS AND NON-CELL ANALYTES IN A SAMPLE IN PARALLEL | July 2020 | October 2023 | Allow | 39 | 4 | 0 | Yes | No |
| 16932532 | MULTIPLEX LATERAL FLOW ASSAY FOR DIFFERENTIATING BACTERIAL INFECTIONS FROM VIRAL INFECTIONS | July 2020 | October 2023 | Allow | 39 | 5 | 1 | Yes | No |
| 16932533 | MULTIPLEX LATERAL FLOW ASSAY FOR DIFFERENTIATING BACTERIAL INFECTIONS FROM VIRAL INFECTIONS | July 2020 | November 2023 | Allow | 40 | 5 | 0 | Yes | No |
| 16882447 | Using Exhaled Breath Condensate, Aerosols and Gases for Detecting Biomarkers | May 2020 | June 2024 | Allow | 49 | 4 | 1 | Yes | No |
| 16876054 | Using Exhaled Breath Condensate for Testing for a Biomarker of COVID-19 | May 2020 | February 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 16753661 | METHODS OF DETECTING TRANSTHYRETIN | April 2020 | October 2024 | Allow | 55 | 1 | 1 | Yes | No |
| 16834474 | SYSTEM AND METHOD FOR DETECTING PATHOGENS ON TREATED AND UNTREATED SUBSTRATES USING LIQUID CRYSTAL CHROMONIC AZO DYE | March 2020 | September 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16616923 | SINGLE-STEP ATPS ENHANCED LFA DIAGNOSTIC DESIGN | November 2019 | February 2026 | Abandon | 60 | 6 | 1 | Yes | No |
| 16656658 | EFFICIENT CAPTURE OF MAGNETIC AND PARAMAGNETIC CARRIERS OF BIOMARKERS FROM A FLOWING SYSTEM | October 2019 | May 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16492431 | IMMUNOCHROMATOGRAPHIC DEVICE FOR EXTRACTING AND MEASURING SUGAR CHAIN ANTIGEN | September 2019 | March 2026 | Abandon | 60 | 4 | 2 | No | No |
| 16484035 | QMAX ASSAY AND APPLICATIONS (II) | August 2019 | November 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16308145 | IMMUNOCHROMATOGRAPHIC TEST PIECE AND SPECIMEN ADDING DEVICE FOR EXTRACTING AND MEASURING SUGAR CHAIN ANTIGEN, AND IMMUNOCHROMATOGRAPHY METHOD USING SAME | December 2018 | October 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16144533 | FLUID TEST CARTRIDGE, FLUID TEST APPARATUS INCLUDING THE SAME, AND METHOD FOR CONTROLLING THE FLUID TEST APPARATUS | September 2018 | September 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 15779933 | ELECTROMAGNETIC ASSEMBLIES FOR PROCESSING FLUIDS | May 2018 | April 2024 | Abandon | 60 | 5 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner LUSI, ELLIS FOLLETT works in Art Unit 1677 and has examined 53 patent applications in our dataset. With an allowance rate of 56.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner LUSI, ELLIS FOLLETT's allowance rate of 56.6% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LUSI, ELLIS FOLLETT receive 2.36 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LUSI, ELLIS FOLLETT is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +52.1% benefit to allowance rate for applications examined by LUSI, ELLIS FOLLETT. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.6% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.8% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 23.5% are granted (fully or in part). This grant rate is in the 12% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.